Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Phase 2
Terminated
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 5
- Registration Number
- NCT04407442
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Improving Survivorship Care for Older Adults After Chemotherapy
Not Applicable
Recruiting
- Conditions
- Survivorship
- Interventions
- Behavioral: Geriatric Assessment
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 70
- Registration Number
- NCT04405115
- Locations
- 🇺🇸
Community Cancer Institute, Clovis, California, United States
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
Completed
- Conditions
- EczemaAtopic Dermatitis
- Interventions
- Other: SkinTracker Mobile App
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 11
- Registration Number
- NCT04404075
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
Health eHeart BEAT-AFib - Health eHeart Biomarkers of Early Atrial Transformation in Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 3000
- Registration Number
- NCT04404465
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
Active, not recruiting
- Conditions
- Corona Virus InfectionCOVIDPregnancy RelatedEarly Pregnancy
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 7965
- Registration Number
- NCT04388605
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Ocrelizumab in Breastmilk
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT04387110
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Understanding the Role of Gender Inequality and Food Insecurity on Maternal and Child Health
Not Applicable
Completed
- Conditions
- Health Knowledge, Attitudes, Practice
- Interventions
- Behavioral: Sumadhur Aarambha
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 90
- Registration Number
- NCT04383847
- Locations
- 🇳🇵
Community based, Nawalparasi, Nepal
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
- Conditions
- Prostate CancerProstateProstate Adenocarcinoma
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT04377152
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
Phase 2
Recruiting
- Conditions
- Recurrent Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- Drug: Axitinib (VEGF-TKI)Procedure: Cytoreductive Nephrectomy (CN)Procedure: Metastasectomy (MET)Biological: Pembrolizumab
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 84
- Registration Number
- NCT04370509
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Pilot Randomized Controlled Trial of the Effects of Daily Skin-to-skin Contact (PRCTS2S)
Not Applicable
Completed
- Conditions
- Premature Baby 33 to 36 WeeksMother-Infant InteractionOxidative Stress
- Interventions
- Behavioral: Skin-to-skin
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 8
- Registration Number
- NCT04368767
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath